GLP‐1 Receptor Agonists and Cancer Risk in Obesity Treatment
Obesity Reviews, EarlyView.ABSTRACT Obesity is a well‐established risk factor for numerous cancers, with body habitus, especially central adiposity, contributing to increased cancer incidence and worse prognosis. Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), initially developed to treat Type 2 diabetes, have rapidly gained prominence as powerful anti‐obesity agents due ...
Lorne J. Hofseth +6 more
wiley +1 more source
A Comparison of SGLT2 or DPP-4 Inhibitor Monotherapy vs Placebo for Type 2 Diabetes in Adolescents vs Young Adults. [PDF]
J Endocr SocLaffel LM +7 more
europepmc +1 more source
Drug‐Induced Sialolithiasis—A Big‐Data Retrospective Study
Oral Diseases, EarlyView.ABSTRACT Background Sialolithiasis pathophysiology is multifactorial, with systemic medications often hypothesised as a key contributor, particularly in older adults (Drug‐Induced Sialolithiasis). However, robust evidence supporting this theory is limited.
Gal Avishai +5 more
wiley +1 more source
AI/ML-Driven DPP-4 Inhibitor Predictor (d4p_v1) for Enhanced Type 2 Diabetes Mellitus Management: Insights Into Chemical Space, Fingerprints, and Electrostatic Potential Maps. [PDF]
Arch Pharm (Weinheim)Manhas A, Dutta R, Piotto S, Amin SA.
europepmc +1 more source
Effect of a DPP-4 Inhibitor on Orthodontic Tooth Movement and Associated Root Resorption. [PDF]
Biomed Res Int, 2020 Qi J +9 more
europepmc +1 more source
Oral Diseases, EarlyView.ABSTRACT Objectives This study investigated the effect of nonsurgical periodontal therapy (NSPT) on periodontal clinical parameters, active‐matrix metalloproteinase‐8 (aMMP‐8), high sensitivity C‐reactive protein (hsCRP), and glycated hemoglobin (HbA1c), and their relationships in diabetes and prediabetes patients with periodontitis.
Kehinde Adesola Umeizudike +8 more
wiley +1 more source
Assessment of Knowledge and General Attitudes of Primary Care Physicians Toward Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Drugs in the Management of Type 2 Diabetes Mellitus in the Qassim Region. [PDF]
CureusAljulajil F, Rabbani U.
europepmc +1 more source
The inhibition of dipeptidyl- peptidase 4 (DPP-4) is an essential therapy for controlling hyperglycemia in patients with type 2 diabetes (T2DM). However, the role of DPP-4 in cancer is not yet clear, with some studies suggesting that it may either ...
A Niazmand (21482669) +7 more
core
Efficacy and safety of imeglimin add-on to DPP-4 inhibitor therapy in Japanese patients with type 2 diabetes mellitus: An interim analysis of the randomised, double-blind FAMILIAR trial. [PDF]
Diabetes Obes MetabKaku K +4 more
europepmc +1 more source
Liver International Communications, Volume 7, Issue 4, December 2026.ABSTRACT Aim Metabolic syndrome (MetS) is a known risk factor for hepatocellular carcinoma (HCC), but the impact of cumulative MetS burden and changes in MetS status over time remains unclear. This study aimed to assess these associations using a large‐scale Japanese health dataset.
Yutaka Yata +9 more
wiley +1 more source